Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 2Phase NA 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Breast Neoplasms 2767Carcinoma, Non-Small-Cell Lung 2265Prostatic Neoplasms 1427Colorectal Neoplasms 1295Neoplasms 1260Multiple Myeloma 1086Lung Neoplasms 1049Neoplasm Metastasis 995Leukemia, Myeloid, Acute 985Lymphoma 900Melanoma 864Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 753Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Squamous Cell Carcinoma of Head and Neck 618Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 598Brain Neoplasms 593Carcinoma, Renal Cell 587Glioblastoma 573Rectal Neoplasms 565Sarcoma 523Myelodysplastic Syndromes 522Lymphoma, Follicular 516

Interventions

Propranolol 2DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Hemangioma, Cavernous, Central Nervous System × Clear all
NCT05085561 2025-08-06

SYCAMORE

Recursion Pharmaceuticals Inc.

Phase 2 Completed
62 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

NCT03474614 2024-04-19

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

St. Joseph's Hospital and Medical Center, Phoenix

Phase 2 Terminated
4 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

NCT03589014 2022-02-25

Treat_CCM

Mario Negri Institute for Pharmacological Research

Phase 2 Completed
71 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡